Filing Flows › Taysha Gene Therapies (TSHA) › Stock forecast & fair value
Taysha Gene Therapies (TSHA) stock forecast and price target
Taysha Gene Therapies (TSHA) trades at $4.33. 13 analysts' median price target is $12.00 (+177%), from $9.00 to $19.00.
Taysha Gene Therapies' latest quarter
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TSHA stock?
The median of 13 analysts' 12-month targets is $12.00, +177% from $4.33; the range is $9.00 to $19.00. The average rating is none.
Does Taysha Gene Therapies usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is TSHA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.